Lymphoma: all 5,624 studies

Page 28 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.

• Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)WithdrawnNCT04456023Phase 2
• CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell MalignanciesCompletedNCT04450069Phase 1
• Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin LymphomaStatus unknownNCT04447547Not applicable
• LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)Active, not recruitingNCT04446962Phase 1/2
• A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT04444141Phase 1/2
• Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)WithdrawnNCT04439305Phase 2
• A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSLStatus unknownNCT04438044Phase 2
• A Study of ICP-022 in Patients With R/R DLBCLCompletedNCT04438005Phase 2
• Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's LymphomasStatus unknownNCT04435743
• A Single-cell Transcriptome Study in Patients With Non-Hodgkin's LymphomaStatus unknownNCT04434833
• A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT04434196Phase 1
• Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell LymphomaStatus unknownNCT04432402Not applicable
• Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaTerminatedNCT04431635Phase 1
• Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) LymphomaStatus unknownNCT04431089Phase 2
• 4SCAR-CD44v6 T Cell Therapy Targeting CancerTerminatedNCT04427449Phase 1/2
• Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell LymphomaStatus unknownNCT04425824Phase 2
• Home Hospital for LymphomaTerminatedNCT04423848Not applicable
• Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell LymphomaStatus unknownNCT04423549
• Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell LymphomaStatus unknownNCT04423536
• Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin LymphomaStatus unknownNCT04419441
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1CompletedNCT04418141Phase 1
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)Active, not recruitingNCT04416984Phase 1/2
• Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell TherapyCompletedNCT04409314
• GPED Regimen for Relapsed/Refractory or Advanced ENKTCLStatus unknownNCT04405375Phase 2
• A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)Status unknownNCT04398953Phase 2
• Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative StudyCompletedNCT04396119
• Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19CompletedNCT04391946
• Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1)CompletedNCT04386512
• Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT04384484Phase 3
• CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell LymphomaStatus unknownNCT04381741Phase 1
• A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular LymphomaStatus unknownNCT04379167Phase 2
• Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin LymphomaWithdrawnNCT04373083Phase 2
• A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's LymphomaStatus unknownNCT04370405Phase 2
• Positron Nuclide Labeled NOTA-FAPI PET Study in LymphomaStatus unknownNCT04367948Not applicable
• Muscle Stimulation for Physical Function During Stem Cell TransplantCompletedNCT04364256Not applicable
• A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell LymphomaStatus unknownNCT04356846Phase 1
• Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCLCompletedNCT04354402
• Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute LeukemiaCompletedNCT04349306Phase 4
• Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin LymphomaStatus unknownNCT04342936Phase 3
• Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FLTerminatedNCT04342117
• Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell LymphomaStatus unknownNCT04338282Phase 2
• Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCLStatus unknownNCT04337593Phase 2
• Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell LymphomasWithdrawnNCT04334174Phase 2
• A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)Status unknownNCT04324879Phase 2
• TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaCompletedNCT04323657Phase 1/2
• A Multicenter Prospective Study of "High Risk" Molecular Typing in Patients With Adult T Lymphoblastic LymphomaStatus unknownNCT04320992
• Rituximab Combined With Chidamide and Lenalidomide for r/r AITLStatus unknownNCT04319601Not applicable
• A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)Status unknownNCT04306887Phase 2
• A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory LymphomasCompletedNCT04306224Phase 1
• Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's LymphomasTerminatedNCT04305444Phase 2
• A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell LymphomaActive, not recruitingNCT04304040Phase 1/2
• CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHLStatus unknownNCT04303247Early Phase 1
• IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone LymphomaCompletedNCT04298879Phase 2
• Follow Up of High Risk Hodgkin Lymphoma in First Complete RemissionCompletedNCT04298619
• Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II StudyStatus unknownNCT04296786Phase 2
• Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell LymphomaStatus unknownNCT04296461Phase 1
• Diet, Physical Activity and Body Composition Changes During R-CHOPWithdrawnNCT04293900
• Lorlatinib Combinations in Lung CancerStatus unknownNCT04292119Phase 1/2
• Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic LeukemiaStatus unknownNCT04289220Phase 1
• A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedNCT04281420Phase 1
• A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic MalignanciesCompletedNCT04279405Phase 1
• Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaStatus unknownNCT04271800Phase 1/2
• Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With LymphomaActive, not recruitingNCT04270266Not applicable
• Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)Active, not recruitingNCT04268706Phase 2
• A Phase I/Ib Study of NIZ985 Alone and in Combination With SpartalizumabTerminatedNCT04261439Phase 1
• CD19/CD20 Dual-CAR-T in B-cell Lymphoma PatientsCompletedNCT04260932Phase 1
• Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid TumorsWithdrawnNCT04260009Phase 1/2
• Exercise for Elderly Lymphoma PatientsCompletedNCT04259593Not applicable
• Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL)Status unknownNCT04253496
• Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell LymphomaStatus unknownNCT04250324Phase 1
• Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell LymphomaStatus unknownNCT04246359Phase 2
• FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesTerminatedNCT04245722Phase 1
• CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's LymphomaStatus unknownNCT04237428Not applicable
• Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)Status unknownNCT04237168
• Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaActive, not recruitingNCT04234061Phase 2
• Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell LymphomaWithdrawnNCT04233697Phase 1
• A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin LymphomaCompletedNCT04232826Phase 1
• A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04231747Phase 1
• Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell LymphomaWithdrawnNCT04231734Not applicable
• Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell LymphomaWithdrawnNCT04230330Phase 1
• Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin LymphomaWithdrawnNCT04220008Phase 2
• LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell LymphomaTerminatedNCT04219319Phase 1
• REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)TerminatedNCT04218825Phase 2
• CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell MalignanciesActive, not recruitingNCT04214886Phase 1
• Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With RituximabCompletedNCT04214444Phase 3
• PD1-CD19-CART in Patients With r/r B-cell LymphomaCompletedNCT04213469Not applicable
• Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHLStatus unknownNCT04206943Phase 1/2
• A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and LymphomaStatus unknownNCT04204161Phase 1
• Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMTCompletedNCT04194840Not applicable
• Resiliency in Older Adults Undergoing Bone Marrow TransplantCompletedNCT04188678
• LITT and Pembrolizumab in Recurrent Brain MetastasisTerminatedNCT04187872Phase 1
• The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological MalignanciesStatus unknownNCT04184414Early Phase 1
• Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell LymphomaStatus unknownNCT04183569
• Study of LUCAR-20S in Patients With R/R NHLTerminatedNCT04176913Phase 1
• Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell LymphomaStatus unknownNCT04173455Phase 1
• The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin LymphomaStatus unknownNCT04169932Early Phase 1
• Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint InhibitorsCompletedNCT04169321Phase 1
• Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma PatientsCompletedNCT04164368Phase 2
• Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLLStatus unknownNCT04163575Phase 1/2
• Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell LymphomaStatus unknownNCT04163302Phase 2

← Lymphoma overview